



American Journal of Epidemiology & Public Health

Research Article

Epidemiological Study of Helicobacter Pylori Infection in a Population in the Rabat-Sale-Zamour-Zaer Region -

K Laarej¹, R Alami^{1*}, L Bentaleb¹, M Jbilou¹, S El Kabbaj¹, M Elmaouardi² and A Bouklouze²

¹Research Laboratory and Medical Analysis of the Royal Gendarmerie, (Rabat) Morocco

²Research Team Pharmaceutical Pharmacology and Toxicology Laboratory, Faculty of Medicine and Pharmacy, University Mohammed V, (Rabat) Morocco

***Address for Correspondence:** Rachid Alami, Research Laboratory and Medical Analysis of the Royal Gendarmerie, (Rabat) Morocco, Tel: +212-611-303-565; E-mail: alami.rachid89@yahoo.fr

Submitted: 05 February 2020; Approved: 13 February 2020; Published: 14 February 2020

Cite this article: Laarej K, Alami R, Bentaleb L, Jbilou M, et al. Epidemiological Study of Helicobacter Pylori Infection in a Population in the Rabat-Sale Zamour-Zaer Region. American J Epidemiol Public Health. 2020;4(1): 006-009.

Copyright: © 2020 Alami R, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Infection with *H. pylori* is universal, likely to affect all populations, but especially encountered when socio-economic conditions are unfavorable. The prevalence of this infection is 70 to 90% in developing countries, while it represents only 20 to 30% in industrialized countries. To assess the prevalence of *H. pylori* infection in the Rabat-Sale-Zamour-Zaer region, we present a retrospective cohort made up of 3923 patients with gastric symptoms admitted to the LRAM from early 2016 to the end of 2018 for a diagnosis of *H. pylori* infection by the ¹³C-labeled urea breath test. The overall prevalence rate of *H. pylori* infection in this study is 35.89% distributed equally between the two sexes, but partially high among the youngest age group between 14 and 39 years (41.24%).

Keywords: *H. pylori*; Prevalence; Epidemiology; Urea test

INTRODUCTION

Chronic bacterial *H. pylori* infection affects an average of 50% of the world's population. This high prevalence is very unevenly distributed in the world, in fact in non-developed countries which can reach 90% [1-3] while it is lower in industrialized countries [4,5]. For example in South America, Bangladesh, and Pakistan the prevalence is 80%, while it is 26% in Switzerland, 11% in Sweden and 20% to 50% in France [5]. The most affected populations in industrialized countries are people of low socio-economic status and those from developing countries. The prevalence in industrialized countries has been decreasing sharply for several decades, probably due to the increase in the standard of living, hygienic conditions and the heavy use of antibiotics [6]. In industrialized countries, the prevalence increases gradually with age. The infection rate is 5 to 10% in children and reaches 20 to 50% in adults. This gradual increase is due to a cohort effect. The infection is acquired in childhood, especially since the socio-economic level is low and persists throughout the life of the individual in the absence of effective treatment. There is very little acquisition in adulthood [7]. The prevalence for a given age group is therefore a reflection of the prevalence of infection in early childhood in the population of this age group. In adults, the infection rate is less than 1% per year. The incidence in children in industrialized countries is considered to be 1% per year compared to 3 to 10% in developing countries [4]. In Africa, the overall prevalence is between 70 and 98% of the population [1-3]. In Morocco, *H. pylori* infection concerns 70% of the population [6,7]. A retrospective cohort made up of 3619 cases, all presenting gastroduodenal warning signs [8], collected over a period of 5 years, found an overall prevalence around 67.4%. This prevalence has declined gradually since 1996. The numerous works published over the past ten years have demonstrated the pathogenic role of *H. pylori* for the gastro-duodenal mucosa, in particular its involvement in gastric and duodenal ulcer disease and in the majority of chronic gastritis [9].

H. pylori infection is often associated with cancer in humans. The most recent data indicate that this bacterium not only plays an initiating role but that it is also involved in the last stages of carcinogenesis [10]. Other recent studies have shown the link between *H. pylori* infection and certain pathologies such as iron deficiency anemia, bronchiectasis, type II diabetes and certain neurological diseases [11].

In this study, we wanted to assess the prevalence of *H. pylori* infection in the Rabat-Sale-Zamour-Zaer region by the ¹³C urea breath test (TRES) in patients with gastric symptoms and compare this prevalence according to different factors (Age, sex, etc.).

MATERIALS AND METHODS

Study location and period

This is a retrospective study carried out over a period of 3 years (January 2016-January 2019) at the Laboratory of Research and Medical Analysis of the Royal Gendarmerie in Rabat (LRAM).

Population studies

The study concerned patients, adults of both sexes admitted to the LRAM.

Inclusion criteria: All patients over the age of 14, of both sexes, who had undergone a ¹³C urea breath test (TRES) without any medical treatment to eradicate *H. pylori* or were included in the study after stopping more than 4 weeks of antibiotic treatment.

Exclusion criteria: Patients excluded from the study are children aged less than 14 years.

Methodology of the study

This epidemiological study is carried out by statistical analysis and interpretation of the results of the TRES analyzes carried out at LRAM. The TRES is rapid and based on the strong urease activity of *H. pylori*. After oral administration of ¹³C urea (stable carbon isotope), the ¹³CO₂ enrichment of the exhaled gases indicates a urease activity signifying the presence of *H. pylori*. This non-invasive test is simple to perform (specificity > 98% / sensitivity > 95%). It also allows the diagnosis and evaluation of the eradication of *H. pylori* after treatment.

Statistical methods

Statistical analyzes were performed to assess the following determinants of *H. pylori* infection; age, gender. For quantitative variables, means, standard deviations, medians and Interquartiles (IQR) were calculated. The proportions were established for the qualitative variables with their 95% Confidence Intervals (CI). To examine the relationship between two discrete variables, we calculated the Relative Risks (RR) and used Pearson's X² test with the Yates correction and the Fischer's exact test for reduced numbers, for a significance level admitted at 5%.

RESULTS

Total population studies

During the study period, 5850 results were collected from January 1, 2016 to the end of December 2018 at LRAM. A total of 3923 (67.06%, 3923/5850) subjects met the inclusion criteria and were tested for *H. pylori* infection with TRES. 1927 subjects excluded from the study because their ages were less than 14 years or their results were not determinate or when the subjects were under medical treatment to

eradicate *H. Pylori*. Among these 1,419 men (36.17%) and 2,504 women (63.82%) of average age 48.5 ± 33.5 years (range 14-89 years), divided into age groups under 40 years 37% (1458/3923), 40-59 years 39.46% (1548/3923) and over 60 years 23.54% (923/3923) (Table 1).

Demographic break down

Global distribution of *H. pylori* infection: The results obtained from this study lead to a significantly lower prevalence of *H. pylori* infection in our population than the figures found in previous studies [8]. It is 35.89% (34.08% in 2016, 32.55% in 2017 and 38.95 in 2018) (Figure 1 and Table 2).

Gender distribution of *H. pylori* infection: Our study series shows that *H. pylori* infection is positive in 37.06% of men and 35.34% of women with a non-significant statistical difference. χ^2 is around 1.08; χ . The calculated value of $2 = 3.84$ at the 5% threshold. χ^2 (χ this value is less than the theoretical. These figures allow us to accept the null hypothesis concerning the independence of the two characteristics. It is concluded that gender has no significant effect on the prevalence of *H. pylori* infection.

Age distribution of *H. pylori* infection: The prevalence of *H. pylori* infection varied significantly with age. χ^2 at 5%, allows us to reject the independence hypothesis and to conclude that age conditions the prevalence of *H. pylori* infection, which was high among the subjects of χ^2 being higher than the theoretical χ the observed less than 40 years with 41.24% (601/1458) compared to subjects of 40-59 years 34.56% (535/1548) while it is only 31.05% (285/917) in subjects over the age of 59 (Figure 2 and Table 2).

Distribution of *H. pylori* infection by sex by age groups: The results obtained in this study show that there are as many men as women who are infected with *H. Pylori* in patients under 40 years 50.93%, however and from 40 years the frequency of *H. Pylori* infection becomes higher in men 54.10% (Figure 3 and Table 2).

Table 1: Demographic data of the study.

| Factor | Range | Size / Distribution |
|-------------|-----------------------|---------------------|
| Sex | Men | 1419/3923 (36,17%) |
| | Women | 2504/3923 (63,82%) |
| Age | (14 à 19) years | 181/3923 (4,61%) |
| | (20 à 39) years | 1277/3923 (32,55%) |
| | (40 à 59) years | 1548/3923 (39,46%) |
| | (60 à 79) years | 835/3923 (21,28%) |
| | Ø 80 years | 82/3923 (2,10%) |
| Age and Sex | (14 à 39) years Men | 498/3923 (12,69%) |
| | (40 à 89) years Men | 893/3923 (22,76%) |
| | (14 à 39) years Women | 975/3923 (24,85%) |
| | (40 à 89) years Women | 1557/3923 (39,67%) |




Figure 1: Overall prevalence of *H. pylori* infection.

Table 2: Distribution of *H. pylori* infection.

| Factor | Range | % <i>H. pylori</i> Pos | χ^2 observed | χ^2 calculated |
|-------------|-----------------------|------------------------|-------------------|---------------------|
| Sex | Men | 37,06% | 1,08 | 3,84 |
| | Women | 35,34% | | |
| Age | (14 à 19) years | 41,22% | 2,49 | 9,489 |
| | (20 à 39) years | 41,26% | 17,39 | |
| | (40 à 59) years | 34,56% | 0,84 | |
| | (60 à 79) years | 27,41% | 22,79 | |
| | Ø 80 years | 34,69% | 0,04 | |
| Age and Sex | (14 à 39) years Men | 41,20% | - | - |
| | (40 à 89) years Men | 35,41% | - | - |
| | (14 à 39) years Women | 41,27% | - | - |
| | (40 à 89) years Women | 29,80% | - | - |




Figure 2: Age distribution of *H. pylori* infection.




Figure 3: Distribution of *H. pylori* infection by sex by age group.

DISCUSSION

The socio-economic status and determinants for *H. pylori* infection have been analyzed in several epidemiological studies, [12-14]. Recent studies confirm the association between *H. pylori* and the hygienic conditions linked to poverty in the urban environment on the one hand, and on the other hand, the increased prevalence of *H. pylori* infection among individuals living in community and overcrowding [15,16].

In our study, the prevalence of *H. pylori* infection is particularly high, in subjects under 40 and men without a significant link to sex being confirmed. The prevalence of *H. pylori* infection in our region is decreasing, age and hygienic conditions are determining factors for *H. pylori* infection [15]. 41% of young people aged 14 to 40 are infected with *H. pylori*, while from 40 years only 32% of patients are infected with this bacterium, 54% of which are men, this slight predominance of men can be explain by the consumption of tobacco and alcohol [17,18].

CONCLUSION

The epidemiological study of *H. pylori* infection showed that 35% of the patients included in this study are infected with *H. pylori*, with a slight male prevalence. 41% of the population between 14 and 39 are affected by this pathology. This drop in the prevalence of *H. pylori* infection compared to previous studies is probably linked to the improvement of food and health hygiene conditions in our study region as well as to the development of socio-economic living standards of the population concerned. To prevent the progression and recurrence of this gastric pathology, patients are expected to be followed up after the diagnosis of the disease and during the course of treatment.

REFERENCES

1. Secka O, Berg DE, Antonio M, Corrah T, Tapgun M, Walton R, et al. Antimicrobial susceptibility and resistance patterns among *Helicobacter pylori* strains from The Gambia, West Africa. *Antimicrobial Agents Chem*. 2013; 57: 1231-1237. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/23263004>
2. Oyedeji KS, Smith SI, Coker AO, Arigbabu AO. Antibiotic susceptibility patterns in *Helicobacter pylori* strains from patients with upper gastrointestinal pathology in Western Nigeria. *Br J Biomed Sci*. 2009; 66: 10-13. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/19348120>
3. Asrat D, Kassa E, Mengistu Y, Nilsson I, Wadstrom T. Antimicrobial susceptibility pattern of *Helicobacter pylori* strains isolated from adult dyspeptic patients in Tikur Anbassa University Hospital, Addis Ababa, Ethiopia. *Ethiop Med*. 2004; 42: 79-85. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/16895024>
4. Mégraud F. *H. pylori* antibiotic resistance: Prevalence, importance, and advances in testing. *Gut*. 2004; 53: 1374-1384. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/15306603/>
5. Sherif M, Mohran Z, Fathy H, Rockabrand DM, Rozmajzl PJ, Frenck RW. Universal high-level primary metronidazole resistance in *Helicobacter pylori* isolated from children in Egypt. *J Clin Microbiol*. 2004; 42: 4832-4834. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/15472354>
6. Krejs GJ. Gastric cancer: Epidemiology and risk factors. *Dig Dis*. 2010; 28: 600-603. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/21088409>
7. Granström M, Tindberg Y, Blennow M. Seroepidemiology of *Helicobacter pylori* infection in a cohort of children monitored from 6 months to 11 years of age. *J Clin Microbiol*. 1997; 35: 468-470. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/9003617>
8. Lahbabi M, Alaoui S, El Rhazi K, El Abkari M, Nejjari C, Amarti A, et al. Sequential therapy versus standard triple-drug therapy for *Helicobacter pylori* eradication: Result of the HPFEZ randomized study. *Clin Res Hepatol Gastroenterol*. 2013; 37: 416-421. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/23168228>
9. Attaf N, Cherkaoui N, Choulli MK, Ghazali L, Mokhtari A, Soulaymani A. Profil épidémiologique de l'infection à *helicobacter pylori* dans la région de Gharb-chrarda-Beni Hssen. *Biologie et sante*. 2004; 4: 25-34.
10. EL BIR IZEM B. Lymphome digestif, expérience du CHU d'Annaba (Algerie). *Acta Endoscopica*. 1998; 28: 297.
11. Frederique RICHY. Francis MEGRAUD Centre National de Reference des Campylobacters et Helicobacters, Laboratoire de Bacteriologie, Universite de Bordeaux 2. 33076 Bordeaux Cedex. <http://bit.ly/2SIQUQs>
12. Brown LM. *Helicobacter pylori*: Epidemiology and routes of transmission. *Epidemiol Rev*. 2000; 22: 283-297. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/11218379>
13. Bures J, Kopacova M, Skodova Fendrichova M, Rejchrt S. Epidemiology of *Helicobacter pylori* infection. *Vnitr Lek*. 2011; 57: 993-999.
14. Kim N. Epidemiology and transmission route of *Helicobacter pylori* infection. *Korean J Gastroenterol*. 2005; 46: 153-158. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/16179833>
15. Epplein M, Signorello LB, Zheng W, Peek RM, Michel A, Williams SM, et al. Race, African ancestry, and *Helicobacter pylori* infection in a low-income United States population. *Cancer Epidemiol Biomarkers Prev*. 2011; 20: 826-834. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/21357376>
16. González N, Fernandez L, Perez Perez G, Saona G, Raisler K, Eugenia Torres M, et al. *Helicobacter pylori* infection in Uruguayan patients of African origin: Clinical, endoscopic and genetic characteristics. *Acta Gastroenterol Latinoam*. 2010; 40: 206-210. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/21053478>
17. Statistiques canadiennes sur le cancer 2013. Agence de la Sante publique du Canada, Statistique Canada, Societe canadienne du cancer. 19. <http://bit.ly/2SGZmbX>
18. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends *Helicobacter pylori* screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. *Am J Gastroenterol*. 2008; 103: 510-514. **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed/18341483>